Aclaris Therapeutics, Inc.
NASDAQ:ACRSBiotechnology
+$0.03 today
- Market cap
- $555.14M
- Beta
- 0.80
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$0.54
Volume 2.94M
Average 1.40M
ACRS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Aclaris Therapeutics, Inc.NASDAQ: ACRS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $102K fell 20.3% year over year, ahead of the -25.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -17.1% a year.
Context
- Depreciation & amortization amounted to 5.8% of revenue in FY2025, up 1.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -20.3% holds above the trailing-twelve-month pace of -25.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 454K USD
- Year-over-year change
- -43.7%
- 4-year CAGR
- -16.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 454K | -43.7% |
| FY2024 | 2024-12-31 | 807K | -6.5% |
| FY2023 | 2023-12-31 | 863K | +8.3% |
| FY2022 | 2022-12-31 | 797K | -13.7% |
| FY2021 | 2021-12-31 | 923K | — |
Depreciation & Amortization vs competitors
How ACRS compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -25.9% is the lowest of 9, against a peer median of +3.9%.
- Depreciation & amortization amounts to 6.3% of revenue for ACRS, versus a peer median of 53.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $3.53M USD | +5.4% | +140.9% | 47.7% |
| LTM Mar 2026 | $3.08M USD | +114.9% | +496.0% | — | |
| LTM Mar 2026 | $2.43M USD | +1.2% | +1.2% | 1.0% | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $2.42M USD | +1.1% | — | — |
| FY2025 | $804K USD | +156.9% | — | 59.6% | |
| LTM Mar 2026 | $528K USD | -25.9% | -17.1% | 6.3% | |
| LTM Mar 2026 | €377.74K EUR | -20.5% | -12.3% | 1287.9% | |
| LTM Mar 2026 | $257.68K USD | +3.1% | -0.9% | — | |
| LTM Mar 2026 | $158K USD | +4.6% | +29.7% | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ACRS) | — | +3.9% | +15.5% | 53.6% | |
Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (90.87M) | (86.91M) | (88.48M) | (132.07M) | (64.92M) |
| Depreciation & Amortization | 923K | 797K | 863K | 807K | 454K |
| Deferred Income Tax | 752K | 0 | (367K) | 0 | 0 |
| Stock-Based Compensation | 14.06M | 15.04M | 20.54M | 10.86M | 12.38M |
| Change in Working Capital | (1.34M) | (1.2M) | 9.39M | 10.92M | 2.67M |
| Accounts Receivables | 149K | 139K | 186K | (20K) | 6.14M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.66M | 368K | (1.47M) | (4.19M) | 8.45M |
| Other Working Capital | (5.15M) | (1.7M) | 10.68M | 15.13M | (11.91M) |
| Other Non-Cash Items | 24.34M | 4.7M | (20.27M) | 89.41M | 2.3M |
| Operating Cash Flow | (52.13M) | (67.57M) | (78.33M) | (20.08M) | (47.11M) |
| Capital Expenditures | (308K) | (605K) | (1.31M) | (121K) | (111K) |
| Acquisitions (Net) | 167.32M | (13.23M) | 0 | 0 | 0 |
| Purchases of Investments | (235.15M) | (164.75M) | (135.68M) | (119.98M) | (39.73M) |
| Sales of Investments | 67.83M | 177.99M | 183.2M | 86.14M | 89.04M |
| Other Investing Activities | (167.32M) | 13.23M | 0 | (35.81M) | (833K) |
| Investing Cash Flow | (167.63M) | 12.63M | 46.22M | (69.77M) | 48.37M |
| Debt Repayment | (11.48M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 238.2M | 72.74M | 26.71M | 74.91M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.67M) | 123K | (8K) | (377K) | (5.86M) |
| Financing Cash Flow | 225.05M | 72.87M | 26.71M | 74.54M | (5.86M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.29M | 17.93M | (5.4M) | (15.31M) | (4.61M) |
| Free Cash Flow | (52.44M) | (68.17M) | (79.63M) | (20.2M) | (47.11M) |
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.